FirstWord

The companies will co-develop a CNS candidate built around a newly-identified mechanism, sharing responsibilities from discovery through commercialisation.

The complete response letter cited "deficiencies" at a site that manufactures tyrosine kinase inhibitor rivoceranib.

After risvutatug rezetecan met its overall survival endpoint in a Chinese trial, GSK is advancing it outside China across multiple tumour types.

The latest approval marks the first platinum-free regimen cleared for muscle-invasive bladder cancer patients, regardless of cisplatin eligibility.

Sarclisa Escena, administered via the CirCLIQ on-body injector, is approved for multiple myeloma across all indications of the drug's intravenous formulation.

STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), he...

TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Confer...

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of pea...

FirstWord takes stock of the programmes and pharma deals designed to overcome the blood-brain barrier in Alzheimer's disease and beyond.

Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly dosing in hemophilia A participants ...